Teva Pharmaceutical Industries Limited (TEVA) Downgraded by Deutsche Bank AG to “Hold”

Deutsche Bank AG downgraded shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) from a buy rating to a hold rating in a report issued on Friday morning. The firm currently has $14.00 target price on the stock.

Several other equities research analysts have also recently weighed in on TEVA. TheStreet cut shares of Teva Pharmaceutical Industries Limited from a c- rating to a d+ rating in a research report on Friday, August 25th. ValuEngine cut shares of Teva Pharmaceutical Industries Limited from a buy rating to a hold rating in a research report on Friday, September 1st. Evercore ISI set a $38.00 price objective on shares of Teva Pharmaceutical Industries Limited and gave the stock a buy rating in a research report on Wednesday, October 25th. Cantor Fitzgerald set a $17.00 price objective on shares of Teva Pharmaceutical Industries Limited and gave the stock a hold rating in a research report on Thursday, October 26th. Finally, Credit Suisse Group cut shares of Teva Pharmaceutical Industries Limited from a neutral rating to an underperform rating and decreased their price objective for the stock from $25.00 to $13.00 in a research report on Wednesday, August 23rd. Five equities research analysts have rated the stock with a sell rating, nineteen have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Teva Pharmaceutical Industries Limited presently has an average rating of Hold and a consensus price target of $26.29.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded down $2.62 during midday trading on Friday, reaching $11.40. 53,092,575 shares of the company’s stock traded hands, compared to its average volume of 23,401,560. The company has a debt-to-equity ratio of 1.30, a quick ratio of 0.61 and a current ratio of 0.94. Teva Pharmaceutical Industries Limited has a 1 year low of $10.85 and a 1 year high of $42.90. The firm has a market cap of $11,582.40, a PE ratio of 2.63, a P/E/G ratio of 0.56 and a beta of 0.52.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a negative net margin of 24.35% and a positive return on equity of 15.29%. The business had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.72 billion. During the same quarter last year, the company posted $1.25 earnings per share. The company’s revenue was up 12.9% compared to the same quarter last year. analysts expect that Teva Pharmaceutical Industries Limited will post 4.06 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Teva Pharmaceutical Industries Limited (TEVA) Downgraded by Deutsche Bank AG to “Hold”” was first published by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://www.com-unik.info/2017/11/04/teva-pharmaceutical-industries-limited-teva-downgraded-by-deutsche-bank-ag-to-hold.html.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be given a dividend of $0.085 per share. This represents a $0.34 dividend on an annualized basis and a dividend yield of 2.98%. Teva Pharmaceutical Industries Limited’s payout ratio is currently -15.80%.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. San Francisco Sentry Investment Group CA bought a new position in shares of Teva Pharmaceutical Industries Limited during the second quarter valued at about $106,000. Kistler Tiffany Companies LLC lifted its position in shares of Teva Pharmaceutical Industries Limited by 74.7% during the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock valued at $122,000 after purchasing an additional 1,571 shares in the last quarter. Bronfman E.L. Rothschild L.P. lifted its position in shares of Teva Pharmaceutical Industries Limited by 2.6% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock valued at $123,000 after purchasing an additional 94 shares in the last quarter. Cutler Capital Management LLC purchased a new stake in Teva Pharmaceutical Industries Limited during the second quarter worth about $133,000. Finally, Shelter Mutual Insurance Co purchased a new stake in Teva Pharmaceutical Industries Limited during the second quarter worth about $133,000. 56.55% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

What are top analysts saying about Teva Pharmaceutical Industries Limited? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Teva Pharmaceutical Industries Limited and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit